Melatonin in Stroke
A legfontosabb adatok
- Ki végzi
- King Edward Medical University
- Hol
- Pakisztán1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 130 fő, tervezett
- Kezdés
- 2026. okt. 1.
- Várható befejezés
- 2027. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Melatonin
- Placebo
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
- Életkor
- 40 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- Age 40-70 years
- Both male and female participants
- Clinical diagnosis of acute ischemic stroke
- National Institutes of Health Stroke Scale (NIHSS) score of 4-24
- Not undergoing reperfusion therapy
Ki nem vehet részt
- Hemorrhagic stroke or other intracranial pathologies
- Chronic liver disease, chronic kidney disease, or severe systemic illnesses
- History of alcohol or substance abuse
- Known allergy to melatonin
- Diagnosis of a sleep disorder
- History of shift work within the past year
- Age less than 40 years or greater than 70 years
- NIHSS score greater than or equal to 25
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Acute ischemic stroke (AIS) is a leading cause of mortality and disability worldwide, placing a substantial burden on healthcare systems and society.1 Despite intensive advancements in the stroke care, incomplete neurological recovery after stroke is quite common, with many survivors experiencing persistent motor, cognitive, or sensory deficits.2 These long-term impairments significantly affect the quality of life and highlight the need for additional neurorestorative therapies.3,4 The pathophysiology of ischemic stroke involves a complex cascade of events including excitotoxicity, oxidative stress, inflammation, and apoptosis, which contribute to neuronal injury and limit functional recovery.5,6 Current treatment strategies primarily focus on revascularization and supportive care, with limited options available to actively promote neuroprotection and regeneration.7,8 Melatonin, an endogenous neurohormone hormone primarily involved in regulating sleep-wake cycles, has been shown to possess several potential therapeutic properties, including antioxidant, anti-inflammatory, and neuroprotective effects.9 These properties have led to investigate the use of melatonin as an adjunctive treatment for various conditions, including stroke.10,11 However, its potential benefit in recovery of neurological status in patients with acute ischemic stroke remains understudied.12 Pre-clinical studies have demonstrated that melatonin can attenuate ischemia-induced brain injury, reduce infarct size, and improve functional outcomes.13 There is a compelling need to explore novel therapeutic interventions that can target neurological recovery in stroke patients. Exogenous melatonin administration offers a promising avenue for this intervention.14, 15 Preliminary studies have shown that melatonin may protect against acute ischemic stroke by suppressing both inflammatory and oxidative stresses.16 The purpose of this study is to evaluate the effects of exogenous melatonin supplementation on the neurological and functional recovery in patients with acute ischemic stroke, potentially leading to improved clinical outcomes. By addressing this research gap, the study seeks to provide valuable insights into the potential role of melatonin as a therapeutic agent in the management of acute ischemic stroke.
A vizsgálat 2 csoportja
- melatonin groupA vizsgált kezelés
Kezelés: Melatonin
- control groupPlacebo, összehasonlításként
Kezelés: Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Effect of Melatonin Supplementation on Neurological and Functional Recovery in Acute Ischemic Stroke - A Randomized Controlled Trial
- A regiszteradat frissítve
- 2026. november 12.